Status:
UNKNOWN
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
Lead Sponsor:
University of California, Irvine
Collaborating Sponsors:
Janssen, LP
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Ri...
Eligibility Criteria
Inclusion
- are currently taking Risperdal and have been on the medication for at least three weeks
- are diagnosed with schizophrenia
- are able to provide written informed consent
- can safely have an MRI
Exclusion
- are treatment resistant or intolerant to Risperdal
- have participated in another drug study in the past 28 days
- are pregnant or trying to become pregnant or are breastfeeding
- are colorblind
- have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study
- have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant
- certain medications are also exclusionary including aripiprazole.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2011
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00937261
Start Date
July 1 2009
End Date
January 1 2011
Last Update
October 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Irvine
Irvine, California, United States, 92697